Nektar Therapeutics (NKTR)

Sector:Health Care
Super Investor Stats:
Ownership count:0
Ownership rank:--
% of all portfolios:0%
History Portfolio Manager Activity Share change % change to portfolio
Q3  2022
Lee Ainslie - Maverick Capital Sell 100.00% 3,218,382 0.31
Q2  2022
Lee Ainslie - Maverick Capital Reduce 32.85% 1,574,538 0.15
Q1  2022
Lee Ainslie - Maverick Capital Reduce 17.68% 1,029,684 0.10
Q4  2021
Lee Ainslie - Maverick Capital Reduce 0.27% 15,822 0.00
Q2  2021
Lee Ainslie - Maverick Capital Reduce 1.66% 97,243 0.02
Q1  2021
Lee Ainslie - Maverick Capital Reduce 11.98% 797,309 0.15
Q3  2019
Meridian Contrarian Fund Sell 100.00% 93,997 0.62
Q2  2019
Meridian Contrarian Fund Reduce 50.27% 95,000 0.63
Q1  2019
Meridian Contrarian Fund Reduce 23.48% 58,000 0.35
Q1  2018
Meridian Contrarian Fund Reduce 54.19% 233,000 4.06
Q4  2017
Meridian Contrarian Fund Reduce 6.32% 29,000 0.28
Q1  2017
Meridian Contrarian Fund Reduce 6.58% 28,101 0.13
Q3  2016
Meridian Contrarian Fund Reduce 9.63% 45,495 0.15

* "Hold Price" is the last known price at which an investor still held a security. It is the closing price of the security as of the portfolio date (quarter end). This value is only provided when a security is owned by at least two investors. In the case of reporting dates being different, a weighted average price is calculated.